ArticleIDCases2026
An unusual presentation of chronic granulomatous invasive fungal rhinosinusitis: A case report and review of the literature.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Granulomatous chronic invasive fungal rhinosinusitis (GCIFR) is an atypical form of invasive fungal rhinosinusitis which affects immunocompetent middle-aged adults mainly due to Aspergillus flavus. It presents with symptoms like headache, facial pain, and proptosis, primarily affecting the ethmoid and maxillary sinuses, and can lead to serious complications. This report details a unique case of GCIFR treated with antifungal and corticosteroid therapy. Case presentation: A 27-year-old Persian male was admitted with left exophthalmia, diplopia, facial pain, and paresthesia. His symptoms began with a headache and facial pain, which progressed to exophthalmia and retroorbital pain. He has a history of allergic bronchopulmonary aspergillosis (ABPA) and bronchiectasis. Despite previous treatment with Itraconazole and Prednisolone, his condition worsened after stopping the medication. He experienced recurrent respiratory issues and eye problems, leading to a diagnosis of chronic granulomatous invasive fungal rhinosinusitis following a biopsy. MRI revealed fungal masses invading the cavernous sinuses, brain, and left orbit. He was treated with amphotericin B and hydrocortisone, which improved some symptoms but indicated severe, invasive fungal disease with orbital and brain involvement. Conclusion: GCIFR has a favorable outcome than other invasive types of fungal rhinosinusitis although it can present with multiple relapses. Management involves surgical debridement of the affected tissue and prolonged antifungal treatment for at least 6 months to minimize recurrence. Having the condition diagnosed at an early stage and treated prevents aggravated complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.